NeuBase Therapeutics Valuation
| NBSEDelisted Stock | USD 1.62 0.17 9.50% |
Based on Macroaxis valuation methodology, the firm appears to be overvalued. NeuBase Therapeutics secures a last-minute Real Value of $1.54 per share. The latest price of the firm is $1.62. Our model forecasts the value of NeuBase Therapeutics from analyzing the firm fundamentals such as Return On Equity of -0.93, shares owned by insiders of 13.37 %, and Current Valuation of (5.83 M) as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that NeuBase Therapeutics' price fluctuation is very steady at this time. Calculation of the real value of NeuBase Therapeutics is based on 3 months time horizon. Increasing NeuBase Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the NeuBase stock is determined by what a typical buyer is willing to pay for full or partial control of NeuBase Therapeutics. Since NeuBase Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of NeuBase Stock. However, NeuBase Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.62 | Real 1.54 | Hype 1.62 | Naive 1.91 |
The real value of NeuBase Stock, also known as its intrinsic value, is the underlying worth of NeuBase Therapeutics Company, which is reflected in its stock price. It is based on NeuBase Therapeutics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of NeuBase Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of NeuBase Therapeutics helps investors to forecast how NeuBase stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of NeuBase Therapeutics more accurately as focusing exclusively on NeuBase Therapeutics' fundamentals will not take into account other important factors: NeuBase Therapeutics Total Value Analysis
NeuBase Therapeutics is now projected to have valuation of (5.83 M) with market capitalization of 1.42 M, debt of 6 M, and cash on hands of 29.85 M. The negative valuation of NeuBase Therapeutics may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the NeuBase Therapeutics fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(5.83 M) | 1.42 M | 6 M | 29.85 M |
NeuBase Therapeutics Asset Utilization
One of the ways to look at asset utilization of NeuBase is to check how much profit was generated for every dollar of assets it reports. NeuBase Therapeutics secures a negative usage of assets of -0.43 %, losing $0.004303 for each dollar of assets held by the firm. Inadequate asset utilization conveys that the company is being less effective with each dollar of assets it secures. Strictly speaking, asset utilization of NeuBase Therapeutics shows how discouraging it operates for each dollar spent on its assets.NeuBase Therapeutics Ownership Allocation
NeuBase Therapeutics secures 13.37 % of its outstanding shares held by insiders and 12.68 % owned by institutional investors.NeuBase Therapeutics Profitability Analysis
Net Loss for the year was (33.78 M) with profit before overhead, payroll, taxes, and interest of 0.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates NeuBase Therapeutics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in NeuBase Therapeutics and how it compares across the competition.
About NeuBase Therapeutics Valuation
The delisted stock valuation mechanism determines NeuBase Therapeutics' current worth on a weekly basis. Our valuation model uses a comparative analysis of NeuBase Therapeutics. We calculate exposure to NeuBase Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of NeuBase Therapeutics's related companies.NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania. Neu Base operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 33 people.
NeuBase Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as NeuBase Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 1.6 M |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Other Consideration for investing in NeuBase Stock
If you are still planning to invest in NeuBase Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the NeuBase Therapeutics' history and understand the potential risks before investing.
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |